Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Angiosarcoma Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

3 recruiting trials for Angiosarcoma. Eligibility criteria explained in plain English.

TrialFinderData lists 3 Angiosarcoma clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 1 is the largest group at 50% (1 studies); the largest phase groups are Phase 1: 1, Phase 2: 1.

Research is led by Italian Sarcoma Group (1), Angiex, Inc. (1), Instituto do Cancer do Estado de São Paulo (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Observational (other, 1 trial), followed by AGX101, Nivolumab.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
3
Total Trials
3
Recruiting Now
0
Phase 3 Trials
3
Sponsors

Track Angiosarcoma trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT06375941

Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars

This study will be a multi-institutional, prospective, observational study of patients with localized primary AS of any site within ISG and RTR centers. Patients will be treated...

Sponsor: Italian Sarcoma GroupEnrolling: 25019 locations
RECRUITINGPhase 1NCT06440005

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an...

Sponsor: Angiex, Inc.Enrolling: 806 locations
RECRUITINGPhase 2NCT06638931

Agnostic Therapy in Rare Solid Tumors

The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or...

Sponsor: Instituto do Cancer do Estado de São PauloEnrolling: 288 locations

Frequently Asked Questions

There are currently 3 clinical trials for Angiosarcoma, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Angiosarcoma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Angiosarcoma, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.